WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406516
Description: CCT007093 is a potent PPM1D inhibitor or WIP1 inhibitor that selectively reduces viability of human tumour cell lines. CCT007093 enhances liver regeneration and increases the survival rate of mice after major hepatectomy. CT007093 treatment appeares to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
MedKoo Cat#: 406516
Chemical Formula: C15H12OS2
Exact Mass: 272.03296
Molecular Weight: 272.39
Elemental Analysis: C, 66.14; H, 4.44; O, 5.87; S, 23.54
Synonym: CCT007093; CCT-007093; CCT 007093.
IUPAC/Chemical Name: (2E,5E)-2,5-Bis(2-thienylmethylene)-cyclopentanone.
InChi Key: KPFZCKDPBMGECB-WGDLNXRISA-N
InChi Code: InChI=1S/C15H12OS2/c16-15-11(9-13-3-1-7-17-13)5-6-12(15)10-14-4-2-8-18-14/h1-4,7-10H,5-6H2/b11-9+,12-10+
SMILES Code: O=C1/C(CC/C1=C\C2=CC=CS2)=C/C3=CC=CS3
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 272.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Lee JS, Park JR, Kwon OS, Kim H, Fornace AJ Jr, Cha HJ. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. J Dermatol Sci. 2014 Feb;73(2):125-34. doi: 10.1016/j.jdermsci.2013.09.003. Epub 2013 Sep 13. PubMed PMID: 24126074.
2: Pivovarov AS, Murzina GB, Tret'iakova MS, Makhnovskiĭ DA. [Role of serine/threonine and tyrosine protein phosphatases in command Helix lucorum neurons at the cellular correlate of habituation]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013 Mar-Apr;63(2):256-68. Russian. PubMed PMID: 23866612.
3: Buss MC, Read TA, Schniederjan MJ, Gandhi K, Castellino RC. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012 Apr;14(4):440-58. doi: 10.1093/neuonc/nos001. Epub 2012 Feb 29. PubMed PMID: 22379189; PubMed Central PMCID: PMC3309853.
4: Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24. PubMed PMID: 20576088; PubMed Central PMCID: PMC2917036.
5: Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, MarchiÃ² C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17. PubMed PMID: 19293255.